← All trials
NCT03674541
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2018
- Primary completion
- Oct 15, 2019
- Completion date
- Oct 15, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.